November 13, 2019. Dr. Diana Zuckerman describes the types of research needed to reduce harm from the metal and other substances in implanted devices, including joint replacements, cardiac implants, mesh, reproductive devices, and many other types of implants.
Read More »On Medical Treatments & Products
NCHR Testimony on Empagliflozin to Improve Glycemic Control
November 13, 2019. The data on Empagliflozin for managing Type 1 Diabetes is limited and it is not clear if the small improvement seen in the clinical trial is clinically meaningful for patients.
Read More »NCHR Testimony on Vascepa to Reduce Risk for Cardiovascular Events
November 14, 2019. Drugs to help reduce the risk of cardiovascular events save lives. The REDUCE-IT study provides encouraging data that AMR101 [Vascepa (icosapent ethyl) ] may help, but there are some important concerns that must be addressed before approval.
Read More »NCHR’s Comments on the USPSTF’s Recommendation on Screening for Bacterial Vaginosis in Pregnant Persons
November 4, 2019. Given the lack of convincing evidence that screening for bacterial vaginosis leads to a clinical benefit, NCHR supports the USPSTF’s caution in making a recommendation to screen for bacterial vaginosis in pregnant persons to prevent preterm delivery.
Read More »NCHR Testimony on New Contraceptive Patch by Agile Therapeutics
October, 30 2019. The FDA held an Advisory Committee meeting to discuss the safety and effectiveness of a new contraceptive patch by Agile Therapeutics. The Committee voted that the benefits of the patch to prevent pregnancy outweigh the risks.
Read More »